Home » Taligen Therapeutics Acquired for $111 Million
Taligen Therapeutics Acquired for $111 Million
Cambridge biotech Taligen Therapeutics Inc. has been acquired by Alexion Pharmaceuticals Inc., a Connecticut therapeutics firm, for $111 million in an up front cash payment.
Mass High Tech
Mass High Tech
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May